Form SC 13G Atara Biotherapeutics, Filed by: BAUPOST GROUP LLC/MA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Atara Biotherapeutics (ATRA) Reports Q3 Loss of $4.20
November 12, 2014 6:36 AM ESTAtara Biotherapeutics (NASDAQ: ATRA) reported Q3 EPS of ($4.20), versus ($2.59) reported last year.
For earnings history and earnings-related data on Atara Biotherapeutics (ATRA) click here.
... More